Publications by authors named "Lavvina Thiyagarajan"

Purpose: Many copy-number variants (CNVs) are reported to cause a variety of neurodevelopmental disabilities including intellectual disability, developmental delay, autism, and other phenotypes with incomplete penetrance. Therefore, not all individuals with a pathogenic CNV are affected. Penetrance estimates vary between studies.

View Article and Find Full Text PDF

Young women with Neurofibromatosis type 1 (NF1) have a high risk of developing breast cancer and poorer survival following breast cancer diagnosis. International guidelines recommend commencing breast screening between 30 and 35 years; however, the optimal screening modality is unestablished, and previous reports suggest that breast imaging may be complicated by the presence of intramammary and cutaneous neurofibromas (cNFs). The aim of this study was to explore potential barriers to implementation of breast screening for young women with NF1.

View Article and Find Full Text PDF
Article Synopsis
  • Disease-associated polygenic scores (PGS) measure an individual's genetic risk for various conditions by combining data from multiple genetic risk variants, and they are already available for use in Australasia.
  • The Human Genetics Society of Australasia (HGSA) emphasizes the importance of thorough evaluation and evidence-based practices before integrating PGS into clinical settings, highlighting the complexities and limitations of these scores.
  • Ongoing discussions focus on the need for regulatory oversight and improved understanding of PGS's benefits, particularly as they can be applied to numerous health conditions and population health strategies.
View Article and Find Full Text PDF

Women with neurofibromatosis type 1 (NF1) have an increased risk of developing early breast cancer with a poorer prognosis compared to the general population. Therefore, international management guidelines recommend regular screening in women with NF1 starting from 30 to 35 years. As the psychological impacts of breast cancer screening in other high-risk populations cannot be extended to women with NF1, due to increased incidence of cognitive and mental health issues, the psychological harms of breast screening in women with NF1 are unknown.

View Article and Find Full Text PDF